38
Participants
Start Date
February 28, 2015
Primary Completion Date
March 22, 2021
Study Completion Date
March 22, 2021
MT-3724 Phase 1
Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.
MT-3724 Phase 2
Intravenous dosing on Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.
New York University Langone Medical Center, New York
Memorial Sloan-Kettering Cancer Center, New York
University of North Carolina, Chapel Hill
Hospital Universitario QuironSalud Madrid, Madrid
Columbus Regional Research Institute, Columbus
21st Century Oncology - Jacksonville, Jacksonville
Orlando Health, Inc., Orlando
BRCR Medical Center, Plantation
ASCLEPES Research Centers, Weeki Wachee
Rabin Medical Center, Davidoff Cancer Center, Hemato-Oncology Institute, Petah Tikva
University of Illinois, Cancer Center, Chicago
MD Anderson Cancer Center, Houston
UT Health San Antonio Cancer, San Antonio
University of Arizona, Tucson
Innovative Clinical Research Institute, LLC, Whittier
Minsk City Clinical Oncology Center, Minsk
Orlando Health, Inc., Orlando
Healthcare Research Network III, LLC, Tinley Park
Carle Foundation Hospital, Urbana
Norton Healthcare, Inc, Louisville
Grodno University Hospital, Grodno
Cross Cancer Institute, Edmonton
Chaim Sheba Medical Center, Department of Hematology, Ramat Gan
The Tel Aviv Sourasky Medical Center, Department of Hematology and Bone Marrow Transplantation, Tel Aviv
Maria Sklodowska-Curie National Institute of Oncology - National Research Institute, Gliwice
University Hospital in Krakow, Teaching Unit of the Hematology Department, Krakow
Our Doctor Clinical Trials Center, Torun
Institute of Hematology and Transfusion Medicine, Department of Hematology, Warsaw
Clinical Center Kragujevac, Clinic of Hematology, Kragujevac
Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad
Catalan Institute of Oncology (ICO) - Hospital Duran i Reynals, Department of Clinical Hematology, Barcelona
University Hospital Vall d'Hebron (HUVH), Department of Hematology, Barcelona
University Hospital Virgen del Rocio (HUVR), Department of Hematology, Seville
Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston
Princess Margaret Cancer Centre, Toronto
Montreal Oncology Research, Québec
LLC ARENSIA Exploratory Medicine, Tbilisi
ARENSIA Exploratory Medicine,, Chisinau
Frederic Chopin Provincial Teaching Hospital, Teaching Department of Hematology, Rzeszów
Jan Mikulicz Radecki University Hospital in Wroclaw, Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw
"Medical Center of Limited Liability Company Medical Centre Named by Academician Yurii Spizhenko", Kyiv
Lead Sponsor
Molecular Templates, Inc.
INDUSTRY